NASDAQ: EQEquillium Inc Stock
$2.39-0.06 (-2.45%)
Updated Aug 28, 2026
EQ Price
$2.39
Fair Value Price
$0.32
Market Cap
$151.55M
52 Week Low
$0.76
52 Week High
$3.54
P/E
-17.07x
P/B
2.71x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$18.01M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$20M
Beta
0.73
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EQ Overview
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EQ's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
EQ
Ranked#204 of 463
Ranked#204 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.06 | A | |
| $113.88 | A | |
| $6.95 | A |
Be the first to know about important EQ news, forecast changes, insider trades & much more!
EQ News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EQ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EQ ($2.39) is overvalued by 642.93% relative to our estimate of its Fair Value price of $0.32 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
EQ ($2.39) is not significantly undervalued (642.93%) relative to our estimate of its Fair Value price of $0.32 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
EQ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EQ due diligence checks available for Premium users.
Valuation
EQ fair value
Fair Value of EQ stock based on Discounted Cash Flow (DCF)
Price
$2.39
Fair Value
$0.32
Overvalued by
642.93%
EQ ($2.39) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EQ ($2.39) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EQ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EQ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-17.07x
Industry
16.84x
Market
40.58x
EQ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.71x
Industry
5.46x
EQ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EQ's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.7M
Profit Margin
0%
EQ's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$58.7M
Liabilities
$2.7M
Debt to equity
0.05
EQ's short-term assets ($57.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EQ's short-term assets ($57.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EQ's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EQ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.1M
Investing
-$71.0k
Financing
$42.0k
EQ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EQ vs Biotech Stocks
Equillium Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.